| 摘要: |
| 目的 根据国际癌症研究机构发布的2022年全球癌症统计报告，结合性别、年龄、人类发展指数（HDI）等特征分析2022年全球及中国肺癌发病和死亡情况。方法 全球185个国家和地区的肺癌数据来源于GLOBOCAN 2022数据库，HDI根据联合国开发计划署公布的《2021年人类发展报告》数据进行整理。将癌症数据进行年龄、性别、HDI分层，描述全球及中国肺癌流行情况。采用Pearson相关分析评估年龄标化发病率（ASIR）、年龄标化死亡率（ASMR）及死亡发病比（M/I）与HDI之间的相关性。结果 2022年全球肺癌总发病人数为248.1万，位列各癌种发病人数的第1位，ASIR（23.6/10万）位列各癌种的第3位；全球肺癌总死亡人数为181.7万，位列各癌种死亡人数的第1位，ASMR（16.8/10万）位列各癌种的第1位。2022年中国肺癌总发病人数为106.1万，占全球肺癌发病人数的42.8%，位列中国各癌种的第1位，ASIR（40.8/10万）位列中国各癌种的第1位；中国肺癌总死亡人数为73.3万，占全球肺癌死亡人数的40.4%，位列中国各癌种的第1位，ASMR（26.7/10万）位列中国各癌种的第1位。全球及中国男性肺癌发病人数、ASIR、死亡人数、ASMR均高于女性。全球及中国肺癌发病人数、ASIR、死亡人数、ASMR随年龄增长呈现上升趋势，40～44岁年龄组之后增长迅速。各个国家和地区ASIR、ASMR与HDI呈正相关（r＝0.739 3、0.686 5，均P＜0.000 1），M/I与HDI呈负相关（r＝－0.688 1，P＜0.000 1）。结论 全球及中国肺癌疾病负担严重，流行情况在不同HDI水平的国家和地区、性别、年龄别之间存在差异。 |
| 关键词: 肺肿瘤 年龄标化发病率 年龄标化死亡率 死亡发病比 人类发展指数 |
| DOI：10.16781/j.CN31-2187/R.20240627 |
| 投稿时间：2024-09-05修订日期：2024-10-14 |
| 基金项目: |
|
| Lung cancer epidemiology in the world and China in 2022 |
| NIE Xiaomeng△,ZHANG Rong△,HUANG Haidong* |
(Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China
△Co-first authors.
* Corresponding author) |
| Abstract: |
| Objective To analyze the incidence and mortality of lung cancer in 2022 globally and in China by combining gender, age, and human development index (HDI) based on the Global Cancer Statistics 2022 issued by the International Agency for Research on Cancer. Methods Lung cancer data from 185 countries and territories worldwide were obtained from the GLOBOCAN 2022 database, and the HDI was organized based on data from the Human Development Report 2021 published by the United Nations Development Program. Cancer data were stratified by age, gender, and HDI to describe the prevalence of lung cancer globally and in China. Pearson correlation analysis was used to assess the correlations between age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), mortality-to-incidence ratio (M/I) and HDI. Results In 2022, the total number of global lung cancer incidence was 2 481 000, ranking the 1st among all cancers, and the ASIR (23.6/100 000) ranked the 3rd among all cancers; the total number of global lung cancer deaths was 1 817 000, ranking the 1st among all cancers, and the ASMR (16.8/100 000) ranked the 1st among all cancers. In 2022, the total number of lung cancer incidence in China was 1 061 000, ranking the 1st among all cancers in China, accounting for 42.8% of the global lung cancer, and the ASIR (40.8/100 000) ranked the 1st among all cancers in China. The total number of lung cancer deaths was 733 000, ranking the 1st among all cancers in China, accounting for 40.4% of the global lung cancer deaths, and the ASMR (26.7/100 000) ranked the 1st among all cancers in China. The number of lung cancer incidence and deaths, ASIR, and ASMR in men were higher than those in women both globally and in China. The incidences of lung cancer, ASIR, deaths and ASMR in the world and China showed an upward trend with age, and then rapidly increased in the group older than 40-44 years group. ASIR and ASMR were positively correlated with HDI (r＝0.739 3, 0.686 5, both P＜0.000 1), while M/I was negatively correlated with HDI (r＝－0.688 1, P＜ 0.000 1) in different countries and territories. Conclusion The burden of lung cancer is serious in the world and China, and the prevalence varies among countries and territories with different HDI levels, genders, and ages. |
| Key words: lung neoplasms age-standardized incidence rate age-standardized mortality rate mortality-to-incidence ratio human development index |
